Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Colombo
N
N
European Institute of Oncology, Milan, Italy.
Peiretti
M
M
Parma
G
G
Lapresa
M
M
Mancari
R
R
Carinelli
S
S
Sessa
C
C
Castiglione
M
M
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000097:blood; D002277:Carcinoma / Q000145:classification / Q000175:diagnosis* / Q000473:pathology; D005060:Europe / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008565:Membrane Proteins / Q000097:blood; D015201:Meta-Analysis as Topic; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D055502:Secondary Prevention; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D018394:CA-125 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins